<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthroplast Today</journal-id><journal-id journal-id-type="iso-abbrev">Arthroplast Today</journal-id><journal-id journal-id-type="pmc-domain-id">3043</journal-id><journal-id journal-id-type="pmc-domain">artd</journal-id><journal-title-group><journal-title>Arthroplasty Today</journal-title></journal-title-group><issn pub-type="epub">2352-3441</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12209938</article-id><article-id pub-id-type="pmcid-ver">PMC12209938.1</article-id><article-id pub-id-type="pmcaid">12209938</article-id><article-id pub-id-type="pmcaiid">12209938</article-id><article-id pub-id-type="pmid">40599325</article-id><article-id pub-id-type="doi">10.1016/j.artd.2025.101749</article-id><article-id pub-id-type="pii">S2352-3441(25)00136-0</article-id><article-id pub-id-type="publisher-id">101749</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Chronic Anticoagulation is Associated With Significantly Increased Rates of Medical Complications, Periprosthetic Joint Infection, and Revision After Primary Total Knee Arthroplasty</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Goel</surname><given-names initials="RK">Rahul K.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Ross</surname><given-names initials="BJ">Bailey J.</given-names></name><degrees>MD</degrees><email>bross7@emory.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Heo</surname><given-names initials="KY">Kevin Y.</given-names></name><degrees>BS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Shah</surname><given-names initials="JA">Jason A.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Schwartz</surname><given-names initials="AN">Andrew N.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Premkumar</surname><given-names initials="A">Ajay</given-names></name><degrees>MD, MPH</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Wilson</surname><given-names initials="JM">Jacob M.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><aff id="aff1"><label>a</label>Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, GA</aff><aff id="aff2"><label>b</label>Adult Hip and Knee Reconstruction, Piedmont Orthopedics/OrthoAtlanta, Newnan, GA</aff><aff id="aff3"><label>c</label>Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, NC</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Department of Orthopaedic Surgery, Emory University School of Medicine, 21 Ortho Lane, Atlanta, GA 30329. Tel.: +1 404 778 3350. <email>bross7@emory.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2025</year></pub-date><volume>34</volume><issue-id pub-id-type="pmc-issue-id">491465</issue-id><elocation-id>101749</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-02 09:25:46.357"><day>02</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>The proportion of patients undergoing total knee arthroplasty (TKA) who are on chronic anticoagulation (CA) is increasing. As existing literature is limited, the purpose of this study was to compare complication rates after primary TKA among patients who were vs were not on CA.</p></sec><sec><title>Methods</title><p>This is a retrospective cohort study using the IBM MarketScan databases. Patients who underwent primary TKA were dichotomized into the CA or control cohort based upon the presence or absence, respectively, of claims for direct oral anticoagulants, warfarin, or low-molecular-weight heparin within 6 months both before and after TKA. Rates of readmissions, medical complications within 90 days, periprosthetic joint infection (PJI), and all-cause revision at 2 years were compared with multivariable logistic regression.</p></sec><sec><title>Results</title><p>A total of 181,760 patients met inclusion criteria, including 13,967 (7.7%) on CA. At 90 days, the CA cohort exhibited significantly higher rates of sepsis (0.9 vs 2.2%; odds ratio (OR) 1.7; <italic toggle="yes">P</italic> &lt; .001), hematoma (0.3 vs 0.7%; OR 1.7; <italic toggle="yes">P</italic> &lt; .001), wound dehiscence (1.2 vs 2.1%; OR 1.4; <italic toggle="yes">P</italic> &lt; .001), and readmission (6.1 vs 14.2%; OR 2.5; <italic toggle="yes">P</italic> &lt; .001). At 2 years, rates of PJI (0.4 vs 1.1%; OR 2.4; <italic toggle="yes">P</italic> &lt; .001) and all-cause revision (2.3 vs 3.4%; OR 1.5; <italic toggle="yes">P</italic> &lt; .001) were significantly higher in the CA cohort.</p></sec><sec><title>Conclusions</title><p>CA was associated with significantly higher rates of readmission, medical complications, PJI, and all-cause revision after primary TKA. This data highlights the importance of preoperative medical optimization and perioperative medical management in this population.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Total knee arthroplasty</kwd><kwd>Perioperative management</kwd><kwd>Complications</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Total knee arthroplasty (TKA) is the standard of care for surgical treatment of end-stage knee osteoarthritis [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. Advances in surgical and anesthetic technique, implant technology, and perioperative management have further improved this operation [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. As a result, TKA has become a safer operation for medically frail patients [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>].</p><p id="p0015">Among patients with medical comorbidities seeking TKA, a subset are on chronic anticoagulation (CA) for the management of various medical conditions. Data from the general surgery literature have illustrated that this patient cohort has high complication risk, including perioperative bleeding and thromboembolic complications [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>]. While improved perioperative management may mitigate some of these complications, concerns remain. Additionally, despite the large number of patients undergoing TKA who are on CA, there are limited existing analyses of the impact of CA on postoperative complications beyond 90 days after TKA relative to controls [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>]. Much of the existing literature has largely analyzed the differential risk of venous thromboembolism (VTE) and other short-term complications associated with CA [<xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>]. Focused analyses of complication profiles among patients on CA vs controls have been performed in recent years though have been limited by only including a single indication for CA (eg, atrial fibrillation) and evaluating short-term complications (ie, within 90 days), with mixed results [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>]. There is a paucity of data on complication rates at longer-term follow-ups in this population relative to patients not on CA.</p><p id="p0020">Therefore, the aim of the present study was to compare postoperative outcomes after primary TKA among patients who were and were not on CA. It was hypothesized that CA would be associated with significantly higher rates of medical complications, prosthesis-related complications, and revisions at 90 days and 2 years postoperatively.</p></sec><sec id="sec2"><title>Material and methods</title><sec id="sec2.1"><title>Data source</title><p id="p0025">A retrospective cohort study was conducted using the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefit databases (Merative L.P., Ann Arbor, MI). The database contains deidentified claims data for over 240 million patients, including diagnoses and procedures associated with both inpatient and outpatient encounters as well as prescription drug data. The Institutional Review Board of our institution granted the current investigation exemption as it is a retrospective review of publicly available, deidentified data. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="sec2.2"><title>Patient selection</title><p id="p0030">The database was queried from 2016 through 2022 to identify all patients undergoing primary TKA. These patients were identified using the Current Procedural Terminology code 27447. Patients undergoing revision procedures, patients &#8804;18 years old, and those without continuous enrollment for at least 6 months before and 6 months after TKA were excluded. Requiring 6-month preoperative and postoperative continuous enrollment was necessary to accurately curate the CA cohort, mitigate transfer bias, and collect postoperative complication data.</p><p id="p0035">The study population was then queried for anticoagulation medication prescriptions within 6 months before TKA, including the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, apixaban, and edoxaban, low-molecular-weight heparin (LMWH), and warfarin. Within this population, the CA cohort was defined as patients who filled at least 1 prescription for these medications both within 6 months before TKA and within 6 months postoperatively to isolate patients who were truly on long-term anticoagulation at the time of TKA. The control cohort was defined as patients without a prescription for any of these anticoagulants within 6 months before the index TKA.</p></sec><sec id="sec2.3"><title>Baseline patient data and postoperative complications</title><p id="p0040">Baseline patient demographic data and clinical characteristics were obtained including age, sex, Charlson Comorbidity Index (CCI), medical comorbidities, inpatient or outpatient designation, and mean length of stay (LOS). Queried comorbidities were defined by associated International Classification of Diseases, 10th revision diagnosis codes and included obesity (body mass index &#8805; 30), chronic liver disease, myocardial infarction, malignancy, chronic kidney disease, alcohol use disorder, tobacco use, peripheral vascular disease, hypertension, coronary artery disease, hyperlipidemia, congestive heart failure, rheumatic disease, diabetes mellitus, thrombophilia, depression, and anxiety. Additionally, the prevalence of common diagnoses associated with CA were obtained for both cohorts, including atrial fibrillation, atrial flutter, valvular heart disease, chronic deep vein thrombosis (DVT), and chronic hypercoaguable state inclusive of patients with Factor V Leiden, Protein C/S deficiency, prothrombin gene mutation, antithrombin deficiency, antiphospholipid syndrome, or other unspecified thrombophilia.</p><p id="p0045">Rates of complications at 90 days postoperatively were queried, including prolonged LOS (<inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8805;</mml:mo></mml:mrow></mml:math></inline-formula> 3 days), periprosthetic joint infection (PJI), surgical site infection (SSI), sepsis, mechanical complications, periprosthetic fracture, hematoma formation, seroma formation, pneumonia, wound dehiscence, and inpatient readmissions. Additionally, rates of PJI, aseptic revision, periprosthetic fracture, mechanical complications, and all-cause revision at 2 years postoperatively were obtained. PJI was defined using diagnosis codes paired with procedural codes for (a) single-component revision with debridement, antibiotics, and implant retention, (b) removal of hardware with insertion of an antibiotic spacer, or (c) 2-component revision TKA (ie, single-stage revision).</p></sec><sec id="sec2.4"><title>Study population</title><p id="p0050">After inclusion and exclusion criteria were applied, 181,760 patients were included in the analysis: 13,967 (7.7%) patients on preoperative CA and 167,793 (92.3%) controls (<xref rid="tbl1" ref-type="table">Table 1</xref>). The CA cohort was significantly older (65.1 vs 61.8 years, <italic toggle="yes">P</italic> &lt; .001), had a significantly higher proportion of men (48.9 vs 40.3%, <italic toggle="yes">P</italic> &lt; .001), and had a significantly higher mean CCI score (2.8 vs 2.2, <italic toggle="yes">P</italic> &lt; .001). Additionally, aside from anxiety, rates of all queried comorbidities were significantly higher in the CA cohort (all <italic toggle="yes">P</italic> &lt; .001). The proportion of patients who underwent primary TKA in an inpatient setting was significantly higher in the CA cohort (14.2 vs 6.1%, <italic toggle="yes">P</italic> &lt; .001) and mean LOS was significantly longer (0.51 vs 0.27 days, <italic toggle="yes">P</italic> &lt; .001).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Demographics and comorbidities by cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Parameter</th><th colspan="2" rowspan="1">Anticoagulation status<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th colspan="1" rowspan="1">No CA</th><th colspan="1" rowspan="1">CA</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Total, n (%)</td><td colspan="1" rowspan="1">167,793 (92.3)</td><td colspan="1" rowspan="1">13,967 (7.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age, Mean &#177; SD</td><td colspan="1" rowspan="1">61.8 &#177; 8.9</td><td colspan="1" rowspan="1">65.1 &#177; 9.8</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Sex, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">67,611 (40.3)</td><td colspan="1" rowspan="1">6810 (48.9)</td><td rowspan="2" colspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">100,182 (59.7)</td><td colspan="1" rowspan="1">7157 (51.2)</td></tr><tr><td colspan="1" rowspan="1">CCI Score, Mean &#177; SD</td><td colspan="1" rowspan="1">1.9 &#177; 2.2</td><td colspan="1" rowspan="1">2.9 &#177; 2.8</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Location of Surgery, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Inpatient</td><td colspan="1" rowspan="1">10,298 (6.1)</td><td colspan="1" rowspan="1">1980 (14.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Outpatient</td><td colspan="1" rowspan="1">157,195 (93.9)</td><td colspan="1" rowspan="1">11,987 (85.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Average LOS, days (SD)</td><td colspan="1" rowspan="1">0.27 (1.6)</td><td colspan="1" rowspan="1">0.51 (1.9)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Comorbidities, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Peripheral Vascular Disease</td><td colspan="1" rowspan="1">22,433 (13.4)</td><td colspan="1" rowspan="1">3647 (26.1)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic Lung Diseases</td><td colspan="1" rowspan="1">51,587 (30.7)</td><td colspan="1" rowspan="1">5443 (39.0)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mild Liver Disease</td><td colspan="1" rowspan="1">36,662 (21.8)</td><td colspan="1" rowspan="1">3530 (25.3)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic Renal Disease</td><td colspan="1" rowspan="1">14,455 (8.6)</td><td colspan="1" rowspan="1">2215 (15.9)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hyperlipidemia</td><td colspan="1" rowspan="1">122,340 (72.9)</td><td colspan="1" rowspan="1">11,266 (80.7)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Coronary Artery Disease</td><td colspan="1" rowspan="1">31,974 (19.1)</td><td colspan="1" rowspan="1">4.984 (35.7)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Congestive Heart Failure</td><td colspan="1" rowspan="1">11,590 (6.9)</td><td colspan="1" rowspan="1">3306 (23.7)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Diabetes</td><td colspan="1" rowspan="1">30,185 (17.9)</td><td colspan="1" rowspan="1">3509 (25.1)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Rheumatic Disease</td><td colspan="1" rowspan="1">26,506 (15.8)</td><td colspan="1" rowspan="1">2582 (18.5)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Anxiety</td><td colspan="1" rowspan="1">41,516 (24.7)</td><td colspan="1" rowspan="1">3490 (25.0)</td><td colspan="1" rowspan="1">.52</td></tr><tr><td colspan="1" rowspan="1">&#160;Depression</td><td colspan="1" rowspan="1">46,300 (27.6)</td><td colspan="1" rowspan="1">4070 (29.1)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Alcohol Abuse</td><td colspan="1" rowspan="1">5755 (3.4)</td><td colspan="1" rowspan="1">587 (4.2)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Tobacco Use</td><td colspan="1" rowspan="1">35,109 (20.9)</td><td colspan="1" rowspan="1">3180 (22.8)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Obesity</td><td colspan="1" rowspan="1">101,481 (60.5)</td><td colspan="1" rowspan="1">9505 (68.1)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hypertension</td><td colspan="1" rowspan="1">125,016 (74.5)</td><td colspan="1" rowspan="1">12,034 (86.2)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Myocardial Infarction</td><td colspan="1" rowspan="1">7400 (4.4)</td><td colspan="1" rowspan="1">1416 (10.1)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Cerebral Vascular Disease</td><td colspan="1" rowspan="1">20,529 (12.2)</td><td colspan="1" rowspan="1">3020 (21.6)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Malignancy</td><td colspan="1" rowspan="1">19,071 (11.4)</td><td colspan="1" rowspan="1">2335 (16.7)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>SD, standard deviation.</p></fn><fn id="tspara0020"><p>Bolded <italic toggle="yes">P</italic> values indicate statistical significance. Inpatient defined as those with an associated hospital admission recorded in the database.</p></fn></table-wrap-foot></table-wrap></p><p id="p0055">The prevalence of all queried chronic medical conditions commonly associated with the need for CA were significantly higher in the CA cohort (<xref rid="tbl2" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Conditions related to chronic anticoagulant use by cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Diagnoses associated with chronic anticoagulation</th><th colspan="2" rowspan="1">Anticoagulation Status<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th colspan="1" rowspan="1">No CA</th><th colspan="1" rowspan="1">CA</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Total, n (%)</td><td colspan="1" rowspan="1">167,793 (92.3)</td><td colspan="1" rowspan="1">13,967 (7.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Conditions, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Atrial Fibrillation</td><td colspan="1" rowspan="1">7101 (4.2)</td><td colspan="1" rowspan="1">5900 (42.2)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Atrial Flutter</td><td colspan="1" rowspan="1">1353 (0.8)</td><td colspan="1" rowspan="1">1442 (10.3)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Heart Valve Disease</td><td colspan="1" rowspan="1">25,599 (15.3)</td><td colspan="1" rowspan="1">4776 (34.2)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic DVT</td><td colspan="1" rowspan="1">422 (0.2)</td><td colspan="1" rowspan="1">353 (2.5)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Chronic Hypercoagulable State</td><td colspan="1" rowspan="1">2985 (1.8)</td><td colspan="1" rowspan="1">1358 (9.7)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Prior PE</td><td colspan="1" rowspan="1">1366 (0.8)</td><td colspan="1" rowspan="1">739 (5.3)</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Bolded <italic toggle="yes">P</italic> values indicate statistical significance.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.5"><title>Data analysis</title><p id="p0060">All statistical analyses were performed using SPSS, version 28.0 (IBM Corporation, Armonk, NY) with an &#945; level set to 0.05. With respect to demographic data and clinical characteristics, categorical variables were compared with <italic toggle="yes">Chi</italic>-square analysis and continuous variables were compared with the Student's <italic toggle="yes">t</italic>-test.</p><p id="p0065">Rates of postoperative complications were first compared between the cohorts in univariate fashion using <italic toggle="yes">Chi</italic>-square analysis. Subsequently, a multivariable analysis of complication rates was performed using multivariable logistic regression controlling for the following variables: age, sex, CCI [<xref rid="bib17" ref-type="bibr">17</xref>], and all comorbidities which were significantly different with respect to prevalence between cohorts (see <xref rid="tbl1" ref-type="table">Table 1</xref>). Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated for each outcome. Subgroup analyses were performed comparing complication rates for (1) controls vs patients on CA based upon specific anticoagulant, and (2) within the preoperative CA cohort, patients on each specific anticoagulant vs the other anticoagulants.</p></sec></sec><sec id="sec3"><title>Results</title><p id="p0070">Univariate analyses (<xref rid="tbl3" ref-type="table">Table 3</xref>) demonstrated that rates of all queried complications at 90 days and 2 years were significantly higher in the CA cohort (all <italic toggle="yes">P</italic> &lt; .001). When controlling for confounding variables, multivariable logistic regression (<xref rid="tbl4" ref-type="table">Table 4</xref>) demonstrated that preoperative CA was associated with significantly higher rates of extended LOS (5.9 vs 3.2%; OR 1.5; 95% CI, 1.4-1.6), PJI (0.3 vs 0.1%; OR 2.2; 95% CI, 1.5-3.2), sepsis (2.2 vs 0.9%; OR 1.7; 95% CI, 1.5-2.0), mechanical complications (2.7 vs 1.4%; OR 1.7; 95% CI, 1.5-1.9), periprosthetic fracture (0.2 vs 0.1%; OR 1.8; 95% CI, 1.1-2.9), hematoma formation (0.7 vs 0.3%; OR 1.7; 95% CI, 1.3-2.2), seroma formation (0.6 vs 0.2%; OR 1.8; 95% CI, 1.3-2.3), pneumonia (2.1 vs 0.9%; OR 1.3; 95% CI, 1.2-1.5), wound dehiscence (2.1 vs 1.2%; OR 1.4; 95% CI, 1.2-1.7), and inpatient readmissions (14.2 vs 6.1%; OR 2.5; 95% CI, 2.3-2.6) within 90 days.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Univariate analyses of complications between cohorts.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Complications</th><th colspan="1" rowspan="1">No chronic anticoagulation<break/>(n = 167,793)<hr/></th><th colspan="1" rowspan="1">Chronic anticoagulation<break/>(n = 13,967)<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th colspan="1" rowspan="1">%</th><th colspan="1" rowspan="1">%</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">90 D</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Surgical Site Infection</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Sepsis</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hematoma</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Seroma</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Pneumonia</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Wound Dehiscence</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hospital Readmission</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">14.2</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Extended LOS (<inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8805;</mml:mo></mml:mrow></mml:math></inline-formula> 3 d)</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">2 Y</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;All-Cause Revision TKA</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Aseptic Revision</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1"><bold>.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Values are presented as percentages. Bolded <italic toggle="yes">P</italic> values indicate statistical significance. Complication rates presented are cumulative (ie, the 2-y results includes patients from the first 90 d).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Multivariate analyses of CA vs nonchronic anticoagulation (reference group)&#8212;controlled for by age, sex, CCI, and other related comorbidities<xref rid="tbl4fna" ref-type="table-fn">a</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Complications</th><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">90 D</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1"><bold>2.2</bold></td><td colspan="1" rowspan="1"><bold>1.5-3.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Surgical Site Infection</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.8-1.4</td><td colspan="1" rowspan="1">.63</td></tr><tr><td colspan="1" rowspan="1">&#160;Sepsis</td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.5-2.0</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.5-1.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1"><bold>1.8</bold></td><td colspan="1" rowspan="1"><bold>1.1-2.9</bold></td><td colspan="1" rowspan="1"><bold>.01</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hematoma</td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.3-2.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Seroma</td><td colspan="1" rowspan="1"><bold>1.8</bold></td><td colspan="1" rowspan="1"><bold>1.3-2.3</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Pneumonia</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.5</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Wound Dehiscence</td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hospital Readmission</td><td colspan="1" rowspan="1"><bold>2.5</bold></td><td colspan="1" rowspan="1"><bold>2.3-2.6</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Extended Length of Stay (<inline-formula><mml:math id="M3" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8805;</mml:mo></mml:mrow></mml:math></inline-formula> 3 d)</td><td colspan="1" rowspan="1"><bold>1.5</bold></td><td colspan="1" rowspan="1"><bold>1.4-1.6</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">2 Y</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;All-Cause Revision TKA</td><td colspan="1" rowspan="1"><bold>1.5</bold></td><td colspan="1" rowspan="1"><bold>1.3-1.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Aseptic Revision</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.1-1.5</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1"><bold>2.4</bold></td><td colspan="1" rowspan="1"><bold>2.0-3.0</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.5</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.2-2.3</bold></td><td colspan="1" rowspan="1"><bold>.002</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Columns are presented as OR, 95% CI. Bolded data indicate statistical significance. Complication rates presented are cumulative (ie, the 2-y results includes patients from the first 90 d).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0010">Peripheral vascular disease, chronic kidney disease, hyperlipidemia, coronary artery disease, congestive heart failure, diabetes mellitus, thrombophilia, depression, and tobacco use.</p></fn></table-wrap-foot></table-wrap></p><p id="p0075">At 2 years postoperatively, rates of all-cause revision (3.4 vs 2.3%; OR 1.5; 95% CI, 1.3-1.7), aseptic revision (2.3 vs 1.9%; OR 1.3; 95% CI, 1.1-1.5), PJI (1.1 vs 0.4%; OR 2.4; 95% CI, 2.0-3.0), mechanical complications (5.7 vs 3.9%; OR 1.3; 95% CI, 1.2-1.5), and periprosthetic fracture (0.4 vs 0.2%; OR 1.7; 95% CI, 1.2-2.3) were significantly higher in the CA cohort.</p><p id="p0080">Subgroup analysis of complication rates based upon specific anticoagulants yielded similar results, with patients on CA exhibiting significantly higher rates of 90-day and 2-year complications relative to controls regardless of anticoagulant medication (<xref rid="tbl5" ref-type="table">Table 5</xref>). Notably, for each individual anticoagulant, rates of sepsis, mechanical complications, hematoma formation, pneumonia, and readmissions within 90 days and both PJI and all-cause revision at 2 years were significantly higher than controls (all <italic toggle="yes">P</italic> &lt; .005).<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Subgroup analyses of complication rates by specific CA medication (nonchronic anticoagulation as reference)&#8212;controlled for by age, sex, CCI, and other related comorbidities<xref rid="tbl5fna" ref-type="table-fn">a</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Complications</th><th colspan="3" rowspan="1">DOACs n = 8581; CCI = 2.9<hr/></th><th colspan="3" rowspan="1">LMWH n = 1654; CCI = 2.4<hr/></th><th colspan="3" rowspan="1">Warfarin n = 3732; CCI = 3.1<hr/></th></tr><tr><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">90 D</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">0.9-2.7</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1"><bold>3.4</bold></td><td colspan="1" rowspan="1"><bold>1.7-7.0</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.8</bold></td><td colspan="1" rowspan="1"><bold>1.6-4.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Surgical Site Infection</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.7-1.3</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.5-2.1</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">0.9-2.0</td><td colspan="1" rowspan="1">0.18</td></tr><tr><td colspan="1" rowspan="1">&#160;Sepsis</td><td colspan="1" rowspan="1"><bold>1.6</bold></td><td colspan="1" rowspan="1"><bold>1.4-1.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.4</bold></td><td colspan="1" rowspan="1"><bold>1.7-3.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.3-2.1</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1"><bold>1.8</bold></td><td colspan="1" rowspan="1"><bold>1.5-2.1</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.1</bold></td><td colspan="1" rowspan="1"><bold>1.6-2.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.1-1.7</bold></td><td colspan="1" rowspan="1"><bold>0.004</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1"><bold>2.0</bold></td><td colspan="1" rowspan="1"><bold>1.1-3.5</bold></td><td colspan="1" rowspan="1"><bold>0.02</bold></td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">0.3-5.3</td><td colspan="1" rowspan="1">0.71</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.8-3.9</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">&#160;Hematoma</td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.0-1.9</bold></td><td colspan="1" rowspan="1"><bold>0.04</bold></td><td colspan="1" rowspan="1"><bold>2.7</bold></td><td colspan="1" rowspan="1"><bold>1.6-4.3</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.1</bold></td><td colspan="1" rowspan="1"><bold>1.4-3.0</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Seroma</td><td colspan="1" rowspan="1"><bold>1.6</bold></td><td colspan="1" rowspan="1"><bold>1.1-2.2</bold></td><td colspan="1" rowspan="1"><bold>0.007</bold></td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">0.8-3.3</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1"><bold>2.3</bold></td><td colspan="1" rowspan="1"><bold>1.5-3.4</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Pneumonia</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.1-1.5</bold></td><td colspan="1" rowspan="1"><bold>0.009</bold></td><td colspan="1" rowspan="1"><bold>1.6</bold></td><td colspan="1" rowspan="1"><bold>1.1-2.2</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.1-1.8</bold></td><td colspan="1" rowspan="1"><bold>0.002</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Wound Dehiscence</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.9-1.4</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.8-3.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.6</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hospital Readmission</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">2.2-2.5</td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.8</bold></td><td colspan="1" rowspan="1"><bold>3.3-4.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.1</bold></td><td colspan="1" rowspan="1"><bold>1.9-2.4</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Extended LOS (<inline-formula><mml:math id="M4" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8805;</mml:mo></mml:mrow></mml:math></inline-formula> 3 d)</td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.3-1.6</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.9</bold></td><td colspan="1" rowspan="1"><bold>1.5-2.3</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">2 Y</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;All-Cause Revision TKA</td><td colspan="1" rowspan="1"><bold>1.5</bold></td><td colspan="1" rowspan="1"><bold>1.3-1.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.7</bold></td><td colspan="1" rowspan="1"><bold>1.3-2.1</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.4</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Aseptic Revision</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.1-1.5</bold></td><td colspan="1" rowspan="1"><bold>0.002</bold></td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.0-1.8</bold></td><td colspan="1" rowspan="1"><bold>0.03</bold></td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.9-1.5</td><td colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1"><bold>2.1</bold></td><td colspan="1" rowspan="1"><bold>1.6-2.7</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.5</bold></td><td colspan="1" rowspan="1"><bold>2.3-5.2</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.6</bold></td><td colspan="1" rowspan="1"><bold>1.9-3.6</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1"><bold>1.3</bold></td><td colspan="1" rowspan="1"><bold>1.2-1.5</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.5</bold></td><td colspan="1" rowspan="1"><bold>1.3-1.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.2</bold></td><td colspan="1" rowspan="1"><bold>1.0-1.4</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1"><bold>1.8</bold></td><td colspan="1" rowspan="1"><bold>1.2-2.6</bold></td><td colspan="1" rowspan="1"><bold>0.004</bold></td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">0.9-4.2</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">0.8-2.5</td><td colspan="1" rowspan="1">0.28</td></tr></tbody></table><table-wrap-foot><fn><p>Columns are presented as OR, 95% CI. Bolded data indicate statistical significance. Complication rates presented are cumulative (ie, the 2-y results includes patients from the first 90 d).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fna"><label>a</label><p id="ntpara0015">Peripheral vascular disease, chronic kidney disease, hyperlipidemia, coronary artery disease, congestive heart failure, diabetes mellitus, thrombophilia, depression, and tobacco use.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">Within the CA cohort, subgroup analyses comparing each anticoagulant against each other yielded largely comparable complication rates (<xref rid="tbl6" ref-type="table">Table 6</xref>). LMWH was associated with a significantly higher rate of wound dehiscence (OR 0.6; 95% CI, 0.4-0.9) compared to DOACs, and a significantly higher readmission rate compared to both DOACs (OR 0.7; 95% CI, 0.6-0.9) and warfarin (OR 0.7; 95% CI, 0.6-0.8).<table-wrap position="float" id="tbl6" orientation="portrait"><label>Table 6</label><caption><p>Subgroup analyses of complication rates between specific CA medications&#8212;controlled for by age, sex, CCI, and other related comorbidities<xref rid="tbl6fna" ref-type="table-fn">a</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Complications</th><th colspan="3" rowspan="1">DOACs vs LMWH (reference)<hr/></th><th colspan="3" rowspan="1">Warfarin vs LMWH (reference)<hr/></th><th colspan="3" rowspan="1">DOACs vs Warfarin (reference)<hr/></th></tr><tr><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">90 D</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.2-1.4</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.4-2.4</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.3-1.1</td><td colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">&#160;Surgical Site Infection</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.4-2.0</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.5-2.8</td><td colspan="1" rowspan="1">0.62</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.5-1.2</td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="1">&#160;Sepsis</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.5-1.1</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.5-1.2</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.8-1.3</td><td colspan="1" rowspan="1">0.83</td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.3</td><td colspan="1" rowspan="1">0.63</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.5-1.1</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.9-1.6</td><td colspan="1" rowspan="1">0.10</td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">0.3-6.0</td><td colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.2-5.7</td><td colspan="1" rowspan="1">0.83</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.5-2.6</td><td colspan="1" rowspan="1">0.76</td></tr><tr><td colspan="1" rowspan="1">&#160;Hematoma</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.3-1.0</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.5-1.6</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.4-1.0</td><td colspan="1" rowspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">&#160;Seroma</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.5-2.4</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">0.7-3.7</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.4-1.1</td><td colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">&#160;Pneumonia</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.6-1.4</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.7-1.5</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.2</td><td colspan="1" rowspan="1">0.41</td></tr><tr><td colspan="1" rowspan="1">&#160;Wound Dehiscence</td><td colspan="1" rowspan="1"><bold>0.6</bold></td><td colspan="1" rowspan="1"><bold>0.4-0.9</bold></td><td colspan="1" rowspan="1"><bold>0.005</bold></td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.6-1.3</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.6-1.0</td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">&#160;Hospital Readmission</td><td colspan="1" rowspan="1"><bold>0.7</bold></td><td colspan="1" rowspan="1"><bold>0.6-0.9</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.7</bold></td><td colspan="1" rowspan="1"><bold>0.6-0.8</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.9-1.2</td><td colspan="1" rowspan="1">0.10</td></tr><tr><td colspan="1" rowspan="1">&#160;Extended Length of Stay (<inline-formula><mml:math id="M5" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8805;</mml:mo></mml:mrow></mml:math></inline-formula> 3 d)</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.1</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.7-1.1</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.9-1.4</td><td colspan="1" rowspan="1">0.33</td></tr><tr><td colspan="1" rowspan="1">2 Y</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;All-Cause Revision TKA</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.2</td><td colspan="1" rowspan="1">0.59</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.2</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.8-1.3</td><td colspan="1" rowspan="1">0.52</td></tr><tr><td colspan="1" rowspan="1">&#160;Aseptic Revision</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.2</td><td colspan="1" rowspan="1">0.70</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.6-1.3</td><td colspan="1" rowspan="1">0.58</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.8-1.4</td><td colspan="1" rowspan="1">0.77</td></tr><tr><td colspan="1" rowspan="1">&#160;PJI</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.4-1.1</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.5-1.4</td><td colspan="1" rowspan="1">0.59</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.6-1.2</td><td colspan="1" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical Complications</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.7-1.1</td><td colspan="1" rowspan="1">0.43</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.7-1.1</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.9-1.3</td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="1">&#160;Periprosthetic Fracture</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.4-2.1</td><td colspan="1" rowspan="1">0.78</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.3-1.7</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">0.7-2.5</td><td colspan="1" rowspan="1">0.37</td></tr></tbody></table><table-wrap-foot><fn><p>Columns are presented as OR, 95% CI. Bolded data indicate statistically significance. Complication rates presented are cumulative (ie, the 2-y results includes patients from the first 90 d).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl6fna"><label>a</label><p id="ntpara0020">Peripheral vascular disease, chronic kidney disease, hyperlipidemia, coronary artery disease, congestive heart failure, diabetes mellitus, thrombophilia, depression, and tobacco use.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4"><title>Discussion</title><p id="p0090">In contemporary practice, patients with significant comorbidity burdens are increasingly considered candidates for TKA. CA, used for the management of a variety of medical comorbidities, is of obvious importance to orthopedic surgeons. Despite this, there is a paucity of data comparing postoperative outcomes of patients on CA relative to controls beyond the immediate postoperative period. In this study, patients on preoperative CA exhibited significantly higher rates of 90-day complications as well as PJI and all-cause revision at 2 years following primary TKA. The significantly higher rates of PJI and aseptic revision are particularly notable [<xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>].</p><p id="p0095">In this large-scale retrospective study, 7.7% of patients were found to be on CA. The prevalence of CA has steadily increased, predominantly in the management of atrial fibrillation and chronic VTE [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]. Data from the United States Center for Medicare Services Part D Prescription Drug Event dataset demonstrate that the number of patients prescribed CA (through Medicare Part D) increased from less than 3 million patients to over 4 million patients between 2012 and 2017 [<xref rid="bib23" ref-type="bibr">23</xref>]. This represents approximately 10% of the Medicare Part D patient cohort. Therefore, given that the annual incidence of TKA continues to climb and that TKA is often performed in a Medicare-aged population, the number of patients on CA undergoing TKA can also be expected to increase in the coming years. Given the progressive shift toward performing primary TKA in the outpatient setting, our finding that a significantly higher proportion of patients in the CA cohort underwent inpatient TKA highlights the critical need for multidisciplinary preoperative optimization and perioperative medical management in these patients as various clinical and economic factors continue to incentivize outpatient TKA [<xref rid="bib24" ref-type="bibr">24</xref>].</p><p id="p0100">We found that CA was associated with significantly higher rates of wound complications, hematoma formation, and superficial infections within 90 days, regardless of specific anticoagulant. These data differ from a recent analysis by Daher et al who reported a significantly lower rate of wound dehiscence within 30 days among patients on chronic warfarin therapy (OR 0.28; 95% CI, 0.11-0.71) and comparable rates for patients on a DOAC (OR 0.52; 95% CI, 0.25-1.09) [<xref rid="bib12" ref-type="bibr">12</xref>]. Furthermore, higher rates of hematoma formation were found only among patients on warfarin (OR 1.71; 95% CI, 0.94-3.12), though via interpretation of the CI, this was not statistically significant [<xref rid="bib12" ref-type="bibr">12</xref>]. Differences between the present study and Daher et al may be secondary to different patient populations, the fact that only patients on CA for atrial fibrillation were included in their study, and methodological design. The association between wound drainage, hematoma, and infection in arthroplasty is well documented and likely underlies the higher rates of these complications in the CA cohort [<xref rid="bib25" ref-type="bibr">25</xref>].</p><p id="p0105">In a large meta-analysis of complication rates associated with different medications prescribed for postoperative VTE prophylaxis after elective hip and knee arthroplasty, Hughes et al found that warfarin was associated with a significantly higher risk of deep infection and SSI compared to aspirin [<xref rid="bib15" ref-type="bibr">15</xref>]. The present study similarly demonstrated higher rates of SSI and revision for infection among patients on CA compared to controls. Though not specifically evaluated due to limitations of the database, it is reasonable to posit that a majority of the control cohort was prescribed aspirin for postoperative VTE prophylaxis as this cohort lacked any prescription claim for the most common alternate chemoprophylactic agents. Furthermore, use of aspirin for VTE prophylaxis has become significantly more common in recent years, with a recent large-scale retrospective analysis reporting that aspirin is the most common agent prescribed [<xref rid="bib26" ref-type="bibr">26</xref>].</p><p id="p0110">The CA cohort in the present study also exhibited significantly higher rates of extended LOS and medical complications within 90 days postoperatively, even after controlling for baseline comorbidity differences. This result aligns with prior analyses of this topic [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>], though contrasts with prior data from analyses of hip fracture patients. Ueoka et al examined patients undergoing surgical treatment of peritrochanteric and femoral neck fractures and found no statistical difference with respect to LOS, complications, or mortality at 1 year postoperatively between patients receiving CA and those who were not [<xref rid="bib27" ref-type="bibr">27</xref>]. The differences between the present study's results and those reported by Ueoka et al are likely due to differences in baseline risk profiles between the hip fracture and elective TKA populations.</p><p id="p0115">In addition to medical complications, CA was also associated with a significantly higher rate of PJI within 90 days as well as prosthesis-related complications at 2 years, including both aseptic revisions and revisions for PJI, mechanical complications, and periprosthetic fracture. These data align well with 2 large-scale retrospective database studies which both reported significantly higher rates of PJI and revision surgery within 90 days [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. This study builds upon prior work by demonstrating that CA is not only associated with increased complication risk in the short term, but also at 2 years postoperatively. This is important as the results of the present study suggest that the presence of CA may be an independent risk factor for both short-term medical complications and prosthesis-related complications including aseptic and septic revisions within 2 years, highlighting the importance of preoperative medical optimization and close longitudinal surveillance postoperatively.</p><p id="p0120">Specific medical comorbidities have been identified as risk factors for complication and optimization protocols have focused on modifying this risk. For instance, obesity has previously been associated with PJI, as well as postoperative medical complications [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib29" ref-type="bibr">29</xref>]. Diabetes mellitus has also been well established as a risk factor for PJI as well as increased LOS following TKA [<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib31" ref-type="bibr">31</xref>]. Unlike other modifiable risk factors, CA is often not modifiable. However, surgeons should review patient records critically and engage patient's medical doctors preoperatively as some patients may be inappropriately continued on these medications or have inappropriately dosed medications, and this may be optimized before surgery [<xref rid="bib32" ref-type="bibr">32</xref>].</p><p id="p0125">Several factors may underlie the observed association between CA and PJI. First, the presence of anticoagulation increases the rate of hematoma formation, superficial surgical site infections, and wound complications. These events may lead to reoperation, and in this study, the CA cohort exhibited significantly higher rates of wound complications, surgical site infection, hematoma formation, seroma formation, and wound dehiscence within 90 days. CA has been identified in prior work as a risk factor for surgical site drainage, which aligns with our data [<xref rid="bib25" ref-type="bibr">25</xref>]. Furthermore, rates of acute reoperation for PJI within 90 days were significantly higher in the CA cohort. Given the known association of early reoperation with subsequent PJI [<xref rid="bib33" ref-type="bibr">33</xref>], this may account for some of the observed differences in 2-year PJI rates. Lastly, it is possible that patients on CA experience higher rates of blood loss and subsequent transfusion. The incidence of postoperative transfusions was not queried in the present study, but the known association of transfusion and PJI should be acknowledged [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib35" ref-type="bibr">35</xref>].</p><sec id="sec4.1"><title>Limitations</title><p id="p0130">This study is not without the inherent limitations associated with all database studies. Without access to patient medical records, it is possible that some demographic and complication data may been miscoded. There is also a risk of selection bias with the inclusion of only patients who were continuously enrolled for 6 months preoperatively and 6 months postoperatively. While this was necessary for proper patient allocation into cohorts, it has the potential to drive selection bias. Another significant limitation to this study was that rates of postoperative DVT and pulmonary embolism (PE) were not analyzed. The reason for this is that the diagnosis of DVT or PE are often indications for CA, and given the use of a claims database, it is difficult to confidently delineate whether DVT and PE were complications or pre-existing comorbidities. Thus, the ability to accurately analyze these metrics is limited. These outcomes would be best assessed either prospectively or in a multicenter retrospective review. In addition, granular data such as operative time and intraoperative blood loss are not available in the database which are relevant to this topic and may have influenced the results. It was also not possible to characterize medication duration, patient adherence to prescribed CA medications, or the perioperative management of CA medications and whether or not this was appropriately performed (ie, holding for an adequate period preoperatively and postoperatively). For example, bridging protocols utilized in the perioperative period are not available in the database. While there was likely inevitable heterogeneity in how these medications were managed perioperatively, this analysis should accurately reflect current real-life clinical management. Additionally, given that aspirin is available over the counter, it was not possible to query rates of aspirin utilization in the control cohort, though it was reasonably assumed that these patients were prescribed this medication given its routine utilization in the absence of risk factors warranting one of the included CA medications. Similarly, it was not possible to determine if some patients in the CA cohort were also taking aspirin and/or nonsteroidal anti-inflammatory medications, which may have influenced the results. Though less common than agents included in this study, clopidogrel may also be used for anticoagulation after TKA and has been associated with increased bleeding risk [<xref rid="bib36" ref-type="bibr">36</xref>]. Similar to prior analyses [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>], utilization of this medication was not evaluated which may have influenced the results. Lastly, the potential for uncontrolled confounding bias should be acknowledged. Possible confounding bias associated with significant differences between the cohorts with respect to age, sex, and comorbidity burden was mitigated through utilization of multivariable logistic regression. Nonetheless, the severity of these comorbidities is unknown and uncaptured, and other known or unknown confounders could have influenced the results.</p></sec></sec><sec id="sec5"><title>Conclusions</title><p id="p0135">In a contemporary retrospective analysis of 181,760 patients undergoing primary TKA, preoperative CA was associated with significantly higher rates of medical complications, PJI, and readmissions within 90 days postoperatively. Additionally, the CA cohort exhibited significantly higher rates of mechanical complications, aseptic revision, and revision for PJI at 2 years. These data highlight the critical importance of preoperative risk stratification and medical optimization, perioperative medical management, and close clinical monitoring in this high-risk population.</p></sec><sec id="sec6"><title>Conflicts of interest</title><p id="p0140">Andrew Schwartz is on the Speakers bureau/paid presentations Depuy Synthes and Heraeus LLC; is a Paid employee for American Association of Hip &amp; Knee Surgeons; receives Research support from Zimmer Biomet; is on the Medical/Orthopaedic publications editorial/governing board of Journal of Arthroplasty and Arthroplasty Today; and is a Board member/committee appointments for American Association Hip &amp; Knee Surgeons Digital Health committee, American Association Hip &amp; Knee Surgeons Arthroplasty Implant Registry.</p><p id="p0145">Ajay Premkumar is a paid consultant for Accupredict, Smith and Nephew, Stryker, Osgenic, and Naviswiss.</p><p id="p0150">Jacob M. Wilson is a paid consultant for Zimmer Biomet.</p><p id="p0155">The other authors declare there are no conflicts of interest.</p><p id="p0160">For full disclosure statements refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.artd.2025.101749" id="intref0010">https://doi.org/10.1016/j.artd.2025.101749</ext-link>.</p></sec><sec id="sec7"><title>CRediT authorship contribution statement</title><p id="p0165"><bold>Rahul K. Goel:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Bailey J. Ross:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Methodology, Investigation, Formal analysis. <bold>Kevin Y. Heo:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation. <bold>Jason A. Shah:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Methodology, Formal analysis, Data curation, Conceptualization. <bold>Andrew N. Schwartz:</bold> Writing &#8211; original draft, Validation, Supervision, Project administration, Methodology, Formal analysis, Conceptualization. <bold>Ajay Premkumar:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Project administration, Methodology, Formal analysis, Conceptualization. <bold>Jacob M. Wilson:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Conceptualization.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Skou</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Rathleff</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Arendt-Nielsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>O.</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of total knee replacement</article-title><source>N Engl J Med</source><volume>373</volume><year>2015</year><fpage>1597</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa1505467</pub-id><pub-id pub-id-type="pmid">26488691</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Miettinen</surname><given-names>H.J.A.</given-names></name><name name-style="western"><surname>Makirinne-Kallio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kroger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miettinen</surname><given-names>S.S.A.</given-names></name></person-group><article-title>Health-related quality of life after hip and knee arthroplasty operations</article-title><source>Scand J Surg</source><volume>110</volume><year>2021</year><fpage>427</fpage><pub-id pub-id-type="doi">10.1177/1457496920952232</pub-id><pub-id pub-id-type="pmid">32862793</pub-id><pub-id pub-id-type="pmcid">PMC8551429</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Turcotte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Angeles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>A.</given-names></name><name name-style="western"><surname>King</surname><given-names>P.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>J.</given-names></name></person-group><article-title>A rapid recovery protocol applied to total joint arthroplasty reduced readmissions for surgical but not medical reasons over a 5-year period</article-title><source>HSS J</source><volume>17</volume><year>2021</year><fpage>130</fpage><pub-id pub-id-type="doi">10.1177/1556331621998688</pub-id><pub-id pub-id-type="pmid">34421421</pub-id><pub-id pub-id-type="pmcid">PMC8361597</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Poeran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danninger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mazumdar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Opperer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety</article-title><source>BMJ</source><volume>349</volume><year>2014</year><object-id pub-id-type="publisher-id">g4829</object-id><pub-id pub-id-type="doi">10.1136/bmj.g4829</pub-id><pub-id pub-id-type="pmcid">PMC4130961</pub-id><pub-id pub-id-type="pmid">25116268</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Anis</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Acuna</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vakharia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Does increasing patient complexity have an effect on medical outcomes and lengths-of-stay after total knee arthroplasty?</article-title><source>J Knee Surg</source><volume>34</volume><year>2021</year><fpage>1318</fpage><pub-id pub-id-type="doi">10.1055/s-0040-1708850</pub-id><pub-id pub-id-type="pmid">32268402</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Halawi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gronbeck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Metersky</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Eckenrode</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Time trends in patient characteristics and in-hospital adverse events for primary total knee arthroplasty in the United States: 2010-2017</article-title><source>Arthroplast Today</source><volume>11</volume><year>2021</year><fpage>157</fpage><pub-id pub-id-type="doi">10.1016/j.artd.2021.08.010</pub-id><pub-id pub-id-type="pmid">34604486</pub-id><pub-id pub-id-type="pmcid">PMC8473015</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Ercan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bostanci</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ulas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozogul</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Teke</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Postoperative hemorrhagic complications after elective laparoscopic cholecystectomy in patients receiving long-term anticoagulant therapy</article-title><source>Langenbecks Arch Surg</source><volume>395</volume><year>2010</year><fpage>247</fpage><pub-id pub-id-type="doi">10.1007/s00423-009-0483-y</pub-id><pub-id pub-id-type="pmid">19294412</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Cima</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Pemberton</surname><given-names>J.H.</given-names></name></person-group><article-title>Bleeding and thromboembolic outcomes for patients on oral anticoagulation undergoing elective colon and rectal abdominal operations</article-title><source>J Gastrointest Surg</source><volume>15</volume><year>2011</year><fpage>2016</fpage><pub-id pub-id-type="doi">10.1007/s11605-011-1611-x</pub-id><pub-id pub-id-type="pmid">21720925</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Belli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aytac</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Yabanoglu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Karagulle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Parlakgumus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nursal</surname><given-names>T.Z.</given-names></name><etal/></person-group><article-title>Results of surgery in general surgical patients receiving warfarin: retrospective analysis of 61 patients</article-title><source>Int Surg</source><volume>100</volume><year>2015</year><fpage>225</fpage><pub-id pub-id-type="doi">10.9738/INTSURG-D-14-00139.1</pub-id><pub-id pub-id-type="pmid">25692422</pub-id><pub-id pub-id-type="pmcid">PMC4337434</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Lock</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ungeheuer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>P.</given-names></name><name name-style="western"><surname>Swol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brede</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery</article-title><source>Perioper Med (Lond)</source><volume>9</volume><year>2020</year><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13741-020-00170-4</pub-id><pub-id pub-id-type="pmid">33292504</pub-id><pub-id pub-id-type="pmcid">PMC7682086</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balmaceno-Criss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuharski</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Chronic anticoagulation in patients who have atrial fibrillation undergoing outpatient total knee arthroplasty: a retrospective matched cohort study</article-title><source>J Arthroplasty</source><volume>40</volume><year>2025</year><fpage>900</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2024.09.038</pub-id><pub-id pub-id-type="pmid">39357687</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Daher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balmaceno-Criss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuharski</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Anticoagulation in patients with atrial fibrillation undergoing inpatient total knee arthroplasty: a matched analysis</article-title><source>J Orthop</source><volume>63</volume><year>2025</year><fpage>82</fpage><pub-id pub-id-type="doi">10.1016/j.jor.2024.10.054</pub-id><pub-id pub-id-type="pmid">39564088</pub-id><pub-id pub-id-type="pmcid">PMC11570692</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Tischler</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Post</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>I.</given-names></name><name name-style="western"><surname>Orozco</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>A.</given-names></name></person-group><article-title>Patients with atrial fibrillation undergoing total joint arthroplasty increase hospital burden</article-title><source>J Bone Joint Surg Am</source><volume>95</volume><year>2013</year><fpage>1606</fpage><pub-id pub-id-type="doi">10.2106/JBJS.L.00882</pub-id><pub-id pub-id-type="pmid">24005202</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Andronic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Andronic</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ammann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pravin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cubberley</surname><given-names>R.</given-names></name></person-group><article-title>Outcomes of different perioperative management strategies of patients on chronic anticoagulation in elective total hip and knee arthroplasty: a systematic review</article-title><source>Fam Pract</source><volume>41</volume><year>2024</year><fpage>629</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1093/fampra/cmae020</pub-id><pub-id pub-id-type="pmid">38641558</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahfoud</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charalambous</surname><given-names>C.P.</given-names></name></person-group><article-title>Comparison of surgical site infection risk between warfarin, LMWH, and aspirin for venous thromboprophylaxis in TKA or tha: a systematic review and meta-analysis</article-title><source>JBJS Rev</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">e20.00021</object-id><pub-id pub-id-type="doi">10.2106/JBJS.RVW.20.00021</pub-id><pub-id pub-id-type="pmid">33347014</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Prentice</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Winston</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kroger</surname><given-names>E.W.</given-names></name></person-group><article-title>Comparison of 90-day adverse events associated with aspirin and potent anticoagulation use for venous thromboembolism prophylaxis: a cohort study of 72,288 total knee and 35,142 total hip arthroplasty patients</article-title><source>J Arthroplasty</source><volume>38</volume><year>2023</year><fpage>1602</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2023.02.021</pub-id><pub-id pub-id-type="pmid">36805118</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Bannay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaignot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blotiere</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Basson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ricordeau</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The best use of the Charlson comorbidity index with electronic health care database to predict mortality</article-title><source>Med Care</source><volume>54</volume><year>2016</year><fpage>188</fpage><pub-id pub-id-type="doi">10.1097/MLR.0000000000000471</pub-id><pub-id pub-id-type="pmid">26683778</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Lum</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Natsuhara</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Giordani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Meehan</surname><given-names>J.P.</given-names></name></person-group><article-title>Mortality during total knee periprosthetic joint infection</article-title><source>J Arthroplasty</source><volume>33</volume><year>2018</year><fpage>3783</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2018.08.021</pub-id><pub-id pub-id-type="pmid">30224099</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Shahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Maltenfort</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Parvizi</surname><given-names>J.</given-names></name></person-group><article-title>In-hospital mortality in patients with periprosthetic joint infection</article-title><source>J Arthroplasty</source><volume>32</volume><year>2017</year><fpage>948</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2016.09.027</pub-id><pub-id pub-id-type="pmid">27816369</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Sinclair</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Rothfusz</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Klika</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Piuzzi</surname><given-names>N.S.</given-names></name></person-group><article-title>Understanding the 30-day mortality burden after revision total knee arthroplasty</article-title><source>Arthroplast Today</source><volume>11</volume><year>2021</year><fpage>205</fpage><pub-id pub-id-type="doi">10.1016/j.artd.2021.08.019</pub-id><pub-id pub-id-type="pmid">34660865</pub-id><pub-id pub-id-type="pmcid">PMC8502837</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Alcusky</surname><given-names>M.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tjia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lapane</surname><given-names>K.L.</given-names></name></person-group><article-title>Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016</article-title><source>J Am Heart Assoc</source><volume>8</volume><year>2019</year><fpage>e012023</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.012023</pub-id><pub-id pub-id-type="pmid">31046504</pub-id><pub-id pub-id-type="pmcid">PMC6512099</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Goldberger</surname><given-names>Z.D.</given-names></name></person-group><article-title>National trends in ambulatory oral anticoagulant use</article-title><source>Am J Med</source><volume>128</volume><year>2015</year><fpage>1300</fpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2015.05.044</pub-id><pub-id pub-id-type="pmid">26144101</pub-id><pub-id pub-id-type="pmcid">PMC4658248</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Colacci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fralick</surname><given-names>M.</given-names></name></person-group><article-title>Oral anticoagulant utilization in the United States and United Kingdom</article-title><source>J Gen Intern Med</source><volume>35</volume><year>2020</year><fpage>2505</fpage><pub-id pub-id-type="doi">10.1007/s11606-020-05904-0</pub-id><pub-id pub-id-type="pmid">32514896</pub-id><pub-id pub-id-type="pmcid">PMC7403268</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Cochrane</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Jiranek</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Seyler</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>S.P.</given-names></name></person-group><article-title>The removal of total knee arthroplasty from the inpatient-only list has improved patient optimization</article-title><source>J Am Acad Orthop Surg</source><volume>32</volume><year>2024</year><fpage>981</fpage><pub-id pub-id-type="doi">10.5435/JAAOS-D-22-01132</pub-id><pub-id pub-id-type="pmid">38684134</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Pulido</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ghanem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Purtill</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Parvizi</surname><given-names>J.</given-names></name></person-group><article-title>Periprosthetic joint infection: the incidence, timing, and predisposing factors</article-title><source>Clin Orthop Relat Res</source><volume>466</volume><year>2008</year><fpage>1710</fpage><pub-id pub-id-type="doi">10.1007/s11999-008-0209-4</pub-id><pub-id pub-id-type="pmid">18421542</pub-id><pub-id pub-id-type="pmcid">PMC2505241</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Lavu</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Porto</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>C.J.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Acuna</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Parvizi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Low-dose aspirin is the safest prophylaxis for prevention of venous thromboembolism after total knee arthroplasty across all patient risk profiles</article-title><source>J Bone Joint Surg Am</source><volume>106</volume><year>2024</year><fpage>1256</fpage><pub-id pub-id-type="doi">10.2106/JBJS.23.01158</pub-id><pub-id pub-id-type="pmid">38753809</pub-id><pub-id pub-id-type="pmcid">PMC11254562</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Ueoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sawaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goshima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shigemoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>A.</given-names></name></person-group><article-title>The influence of pre-operative antiplatelet and anticoagulant agents on the outcomes in elderly patients undergoing early surgery for hip fracture</article-title><source>J Orthop Sci</source><volume>24</volume><year>2019</year><fpage>830</fpage><pub-id pub-id-type="doi">10.1016/j.jos.2018.12.027</pub-id><pub-id pub-id-type="pmid">30709788</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piuzzi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khlopas</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mont</surname><given-names>M.A.</given-names></name></person-group><article-title>Association between body mass index and thirty-day complications after total knee arthroplasty</article-title><source>J Arthroplasty</source><volume>33</volume><year>2018</year><fpage>865</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2017.09.038</pub-id><pub-id pub-id-type="pmid">29107493</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Zusmanovich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Schwarzkopf</surname><given-names>R.</given-names></name></person-group><article-title>Postoperative complications of total joint arthroplasty in obese patients stratified by BMI</article-title><source>J Arthroplasty</source><volume>33</volume><year>2018</year><fpage>856</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2017.09.067</pub-id><pub-id pub-id-type="pmid">29089223</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Tarabichi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shohat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kheir</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Adelani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brigati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kearns</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Determining the threshold for HbA1c as a predictor for adverse outcomes after total joint arthroplasty: a multicenter, retrospective study</article-title><source>J Arthroplasty</source><volume>32</volume><year>2017</year><fpage>S263</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2017.04.065</pub-id><pub-id pub-id-type="pmid">28662955</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Sobrio</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sculco</surname><given-names>T.P.</given-names></name><etal/></person-group><article-title>Postoperative complications and impact of diabetes mellitus severity on revision total knee arthroplasty</article-title><source>J Knee Surg</source><volume>33</volume><year>2020</year><fpage>228</fpage><pub-id pub-id-type="doi">10.1055/s-0038-1677542</pub-id><pub-id pub-id-type="pmid">30650440</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Meador</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dyke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Togami</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuskov</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>A.E.</given-names></name></person-group><article-title>Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics</article-title><source>J Thromb Thrombolysis</source><volume>53</volume><year>2022</year><fpage>436</fpage><pub-id pub-id-type="doi">10.1007/s11239-021-02551-y</pub-id><pub-id pub-id-type="pmid">34410560</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Osmon</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hanssen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Pagnano</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Abdel</surname><given-names>M.P.</given-names></name></person-group><article-title>Aseptic reoperations within 1 Year of primary total knee arthroplasty markedly increase the risk of later periprosthetic joint infection</article-title><source>J Arthroplasty</source><volume>35</volume><year>2020</year><fpage>3668</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2020.06.054</pub-id><pub-id pub-id-type="pmid">32665159</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melchor</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>da Casa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pescador</surname><given-names>D.</given-names></name></person-group><article-title>Risk factors for periprosthetic joint infection after total knee arthroplasty</article-title><source>Arch Orthop Trauma Surg</source><volume>140</volume><year>2020</year><fpage>239</fpage><pub-id pub-id-type="doi">10.1007/s00402-019-03304-6</pub-id><pub-id pub-id-type="pmid">31707484</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>K.M.</given-names></name></person-group><article-title>Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis</article-title><source>J Arthroplasty</source><volume>32</volume><year>2017</year><fpage>320</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2016.08.026</pub-id><pub-id pub-id-type="pmid">27682006</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Jacob</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Loughran</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wetsch</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Trousdale</surname><given-names>R.T.</given-names></name></person-group><article-title>Continuing clopidogrel during elective total hip and knee arthroplasty: assessment of bleeding risk and adverse outcomes</article-title><source>J Arthroplasty</source><volume>29</volume><year>2014</year><fpage>325</fpage><pub-id pub-id-type="doi">10.1016/j.arth.2013.06.008</pub-id><pub-id pub-id-type="pmid">23856063</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0170">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Heo</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Premkumar</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc3" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Wilson</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc3.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc4" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Goel</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc4.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc5" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Shah</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc5.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc6" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Schwartz</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc6.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc7" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Ross</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc7.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec></back></article></pmc-articleset>